BAXTER INTL DL 1/ US0718131099 /
2024-07-26 9:20:17 PM | Chg. +0.620 | Volume | Bid10:00:01 PM | Ask10:00:01 PM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
32.970EUR | +1.92% | 724 Turnover: 23,738.280 |
32.585Bid Size: 306 | 32.835Ask Size: 304 | 16.67 bill.EUR | - | - |
GlobeNewswire
06-26
Neurona Therapeutics Appoints Dr. Nadia Agopyan as Senior Vice President of Regulatory Affairs
GlobeNewswire
06-20
ProvisionAi COO Terri Bennett Robbins Named One of 20 Women Reshaping the Future of Logistics and th...
GlobeNewswire
06-20
E-fuels offer long-term solution to key energy transition transport sectors, but journey needs to st...
GlobeNewswire
06-14
CMS Improves Star Ratings to 3.5 Stars for Clover Health PPO Medicare Advantage Plans for 2025 Payme...
GlobeNewswire
06-12
2024 RealTrends + Tom Ferry The Thousand List Recognizes 44 eXp Realty Agents and Teams
GlobeNewswire
06-12
2024 Report: LGBTQ+ Advertising Influential Over Brand Perceptions & Purchase Decisions
GlobeNewswire
06-04
Wood Mackenzie appoints Xizhou Zhou as new head of Power and Renewables Business
GlobeNewswire
05-16
US November election results could decelerate energy transition, with $1 trillion in energy investme...
GlobeNewswire
05-15
Investigation Alert Baxter International, Eagle Pharmaceuticals, BioXcel Therapeutics, and ImmunityB...